Literature DB >> 14991930

Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.

Kuo-Shyang Jeng1, I-Shyan Sheen, Yi-Ching Wang, Shu-Ling Gu, Chien-Ming Chu, Shou-Chuan Shih, Po-Chuan Wang, Wen-Hsing Chang, Horng-Yuan Wang.   

Abstract

AIM: To investigate the prognostic value of vascular endothelial growth factor messenger RNA (VEGF mRNA) in the peripheral blood (PB) of patients with hepatocellular carcinoma (HCC) undergoing curative resection.
METHODS: Using a reverse-transcription polymerase chain reaction (RT-PCR)-based assay, VEGF mRNA in the PB was determined prospectively in 50 controls and in 50 consecutive patients undergoing curative resection for HCC.
RESULTS: Among the isoforms of VEGF mRNA, VEGF(165) and VEGF(121) were expressed. By multivariate analysis, a higher level of VEGF(165) in preoperative PB correlated with a risk of HCC recurrence with borderline significance (P=0.050) and significantly with recurrence-related mortality (P=0.048); while VEGF(121) did not. Other significant predictors of HCC recurrence included cellular dedifferentiation (P=0.033), an absent or incomplete capsule (P=0.020), vascular permeation (P=0.018), and daughter nodules (P=0.006). The other significant parameter of recurrence related mortality was cellular dedifferentiation (P=0.053). The level of circulating VEGF mRNA, however, did not significantly correlate with tumor size, cellular differentiation, capsule, daughter nodules, vascular permeation, necrosis and hemorrhage of tumors.
CONCLUSION: The preoperative level of circulating VEGF mRNA, especially isoform VEGF(165), plays a significant role in the prediction of postoperative recurrence of HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991930      PMCID: PMC4716901          DOI: 10.3748/wjg.v10.i5.643

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

Review 1.  Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction.

Authors:  J Folkman
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

2.  Expression of epidermal growth factor and fibroblast growth factor in human hepatocellular carcinoma: an immunohistochemical study.

Authors:  Y Motoo; N Sawabu; Y Nakanuma
Journal:  Liver       Date:  1991-10

3.  Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  J Zhou; Z Y Tang; J Fan; Z Q Wu; X M Li; Y K Liu; F Liu; H C Sun; S L Ye
Journal:  J Cancer Res Clin Oncol       Date:  2000-01       Impact factor: 4.553

4.  Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.

Authors:  N H Chow; P I Hsu; X Z Lin; H B Yang; S H Chan; K S Cheng; S M Huang; I J Su
Journal:  Hum Pathol       Date:  1997-06       Impact factor: 3.466

5.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

6.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  R Yamaguchi; H Yano; A Iemura; S Ogasawara; M Haramaki; M Kojiro
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

7.  Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.

Authors:  T Torimura; M Sata; T Ueno; M Kin; R Tsuji; K Suzaku; O Hashimoto; H Sugawara; K Tanikawa
Journal:  Hum Pathol       Date:  1998-09       Impact factor: 3.466

8.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

10.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.

Authors:  Y Yamamoto; M Toi; S Kondo; T Matsumoto; H Suzuki; M Kitamura; K Tsuruta; T Taniguchi; A Okamoto; T Mori; M Yoshida; T Ikeda; T Tominaga
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

View more
  20 in total

Review 1.  Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.

Authors:  Eleni Liapi; Jean-Francois H Geschwind
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

2.  New agents on the horizon in hepatocellular carcinoma.

Authors:  Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

3.  Targeting metastatic upper gastrointestinal adenocarcinomas.

Authors:  Jennifer L Spratlin; Quincy Chu; Sheryl Koski; Karen King; Karen Mulder
Journal:  World J Clin Oncol       Date:  2011-03-10

4.  Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Anass Touyar; Pr Hassan Errihani
Journal:  N Am J Med Sci       Date:  2011-04

Review 5.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.

Authors:  Geertu Deli; Can-Hao Jin; Rong Mu; Song Yang; Yue Liang; De Chen; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 7.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

8.  Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

9.  Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Authors:  Matthias Pinter; Wolfgang Sieghart; Monika Schmid; Bernhard Dauser; Gerald Prager; Hans Peter Dienes; Michael Trauner; Markus Peck-Radosavljevic
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

10.  Evolving therapies in the treatment of hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.